Use acid-suppressing drugs appropriately with an individualized approach to minimize the risk of infection

被引:0
|
作者
Writers A.M. [1 ]
机构
[1] Springer, Mairangi Bay, Private Bag 65901, Auckland
关键词
D O I
10.1007/s40267-017-0473-z
中图分类号
学科分类号
摘要
Acid-suppressing drugs (ASDs) have been associated with an increased risk of various infections, although causality has not been determined owing to data limitations and conflictions. As such, ASDs should be used cautiously and be limited to appropriate evidence-based settings. ASD regimens should also be individualized (taking into account patient risk factors, likelihood of adverse events and drug interactions) and the overall risks and benefits of the therapy balanced. It may also be prudent to consider adjunctive preventative measures, such as prebiotics, probiotics, increased fibre intake and correction of vitamin D status. © 2017, Springer International Publishing AG, part of Springer Nature.
引用
收藏
页码:67 / 72
页数:5
相关论文
共 50 条
  • [41] Use of Gastric Acid Suppressing Drugs and Subsequent Risk of Celiac Disease; A Population-Based, Case-Control Study
    Lebwohl, Benjamin
    Spechler, Stuart J.
    Green, Peter H.
    Ludvigsson, Jonas F.
    GASTROENTEROLOGY, 2013, 144 (05) : S243 - S243
  • [42] Tranexamic acid: the importance of correct use and individualized risk-benefit analysis
    Pekrul, Isabell
    Schachtner, Thomas
    Zwissler, Bernhard
    Moehnle, Patrick
    ANAESTHESIST, 2021, 70 (07): : 616 - 617
  • [43] Risk Factors for Falls with Use of Acid-Suppressive Drugs
    Cea-Soriano, Luca
    Johansson, Saga
    Garcia Rodriguez, Luis A.
    EPIDEMIOLOGY, 2013, 24 (04) : 600 - 607
  • [44] Evaluation of a risk management plan to minimize concomitant use of ethinyl estradiol/dropirenone and potentially interacting drugs
    McAdams, Mara
    Staffa, Judy
    Gerald, Dal Pan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S179 - S180
  • [45] Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non Small-Cell Lung Cancer Harboring EGFR Mutations
    Zenke, Yoshitaka
    Yoh, Kiyotaka
    Matsumoto, Shingo
    Umemura, Shigeki
    Niho, Seiji
    Ohmatsu, Hironobu
    Goto, Koichi
    Ohel, Yuichiro
    CLINICAL LUNG CANCER, 2016, 17 (05) : 412 - 418
  • [46] A risk assessment approach to use of antimicrobials in the home to prevent spread of infection
    Bloomfield, Sally F.
    Scott, Elizabeth A.
    AMERICAN JOURNAL OF INFECTION CONTROL, 2013, 41 (05) : S87 - S93
  • [47] Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs
    Laheij, RJF
    Sturkenboom, MCJM
    Hassing, RJ
    Dieleman, J
    Stricker, BHC
    Jansen, JBMJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (16): : 1955 - 1960
  • [48] Acid-Reducing Drugs in Pregnancy: Patterns of Use and Risk of Selected Birth Defects
    Bennekom, Carla Mvan
    Mitchell, Allen A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 195 - 196
  • [49] Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis
    Lacaille, Diane
    Guh, Daphne P.
    Abrahamowicz, Michal
    Anis, Aslam H.
    Esdaile, John M.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (08): : 1074 - 1081
  • [50] Use of Nonbiologic Disease-Modifying Antirheumatic Drugs and Risk of Infection in Patients With Rheumatoid Arthritis
    Dejaco, Christian
    Duftner, Christina
    JOURNAL FUR MINERALSTOFFWECHSEL, 2008, 15 (04): : 217 - +